NASDAQ:FLDM - Fluidigm Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.76 +0.11 (+0.81 %) (As of 03/18/2019 01:32 PM ET)Previous Close$13.65Today's Range$13.59 - $13.7852-Week Range$4.65 - $14.50Volume16,871 shsAverage Volume982,624 shsMarket Capitalization$541.08 millionP/E Ratio-17.06Dividend YieldN/ABeta2.4 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California. Receive FLDM News and Ratings via Email Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:FLDM Previous Symbol CUSIP34385P10 CIK1162194 Webwww.fluidigm.com Phone650-266-6000Debt Debt-to-Equity Ratio7.56 Current Ratio1.85 Quick Ratio1.45Price-To-Earnings Trailing P/E Ratio-17.06 Forward P/E Ratio-19.38 P/E GrowthN/A Sales & Book Value Annual Sales$112.96 million Price / Sales4.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book17.20Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-59,010,000.00 Net Margins-52.24% Return on Equity-90.07% Return on Assets-12.20%Miscellaneous EmployeesN/A Outstanding Shares39,323,000Market Cap$541.08 million Next Earnings Date5/2/2019 (Estimated) OptionableOptionable Fluidigm (NASDAQ:FLDM) Frequently Asked Questions What is Fluidigm's stock symbol? Fluidigm trades on the NASDAQ under the ticker symbol "FLDM." How were Fluidigm's earnings last quarter? Fluidigm Co. (NASDAQ:FLDM) released its quarterly earnings results on Thursday, February, 7th. The medical research company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. The medical research company had revenue of $32.33 million for the quarter, compared to analyst estimates of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%. View Fluidigm's Earnings History. When is Fluidigm's next earnings date? Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Fluidigm. What price target have analysts set for FLDM? 4 brokers have issued 12 month target prices for Fluidigm's shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate Fluidigm's stock price to reach $14.3333 in the next year. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for Fluidigm. What is the consensus analysts' recommendation for Fluidigm? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm. Has Fluidigm been receiving favorable news coverage? News headlines about FLDM stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fluidigm earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. Are investors shorting Fluidigm? Fluidigm saw a decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,527,148 shares, a decline of 74.3% from the February 15th total of 5,938,492 shares. Based on an average daily volume of 1,077,758 shares, the short-interest ratio is currently 1.4 days. Approximately 2.6% of the company's stock are short sold. View Fluidigm's Current Options Chain. Who are some of Fluidigm's key competitors? Some companies that are related to Fluidigm include USANA Health Sciences (USNA), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Madrigal Pharmaceuticals (MDGL), Patterson Companies (PDCO), Gerresheimer (GXI), Inogen (INGN), Ironwood Pharmaceuticals (IRWD), PTC Therapeutics (PTCT), Crispr Therapeutics (CRSP), Avanos Medical (AVNS), RESMED/IDR UNRESTR (RMD), The Medicines (MDCO), NxStage Medical (NXTM) and Supernus Pharmaceuticals (SUPN). What other stocks do shareholders of Fluidigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fluidigm investors own include Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Fate Therapeutics (FATE), AbbVie (ABBV), Micron Technology (MU), Freeport-McMoRan (FCX), Allena Pharmaceuticals (ALNA), Viewray (VRAY), Johnson & Johnson (JNJ) and FireEye (FEYE). Who are Fluidigm's key executives? Fluidigm's management team includes the folowing people: Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)Mr. Steven C. McPhail, Chief Commercial Officer (Age 65)Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60) Who are Fluidigm's major shareholders? Fluidigm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Levin Capital Strategies L.P. (24.33%), BlackRock Inc. (5.44%), Millennium Management LLC (2.37%), RTW Investments LP (2.25%), Pura Vida Investments LLC (1.73%) and Acadian Asset Management LLC (1.37%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm. Which institutional investors are selling Fluidigm stock? FLDM stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Connor Clark & Lunn Investment Management Ltd., D. E. Shaw & Co. Inc. and Northern Trust Corp. View Insider Buying and Selling for Fluidigm. Which institutional investors are buying Fluidigm stock? FLDM stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Millennium Management LLC, Pura Vida Investments LLC, Norges Bank, Two Sigma Investments LP, Two Sigma Advisers LP, BlackRock Inc. and Royce & Associates LP. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm. How do I buy shares of Fluidigm? Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fluidigm's stock price today? One share of FLDM stock can currently be purchased for approximately $13.76. How big of a company is Fluidigm? Fluidigm has a market capitalization of $541.08 million and generates $112.96 million in revenue each year. The medical research company earns $-59,010,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. What is Fluidigm's official website? The official website for Fluidigm is http://www.fluidigm.com. How can I contact Fluidigm? Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000. MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 444 (Vote Outperform)Underperform Votes: 270 (Vote Underperform)Total Votes: 714MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/18/2019 by MarketBeat.com StaffFeatured Article: What is Put Option Volume?